Of microbes and meals: The health consequences of dietary endotoxemia

Nutrition in Clinical Practice

Volumn 27, Issue 2, 2012, Pages 215-225

  Kelly, Caleb J ^a   Colgan, Sean P ^a   Frank, Daniel N ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; endotoxemia; endotoxins; inflammation; intestines; lipopolysaccharides; metagenome; obesity; postprandial period

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DETOXIFICATION; DIABETES MELLITUS; DIETARY INTAKE; ENDOTOXEMIA; HUMAN; INFLAMMATION; MEAL; MICROORGANISM; NONHUMAN; OBESITY; REVIEW;

BACTERIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIET; ENDOTOXEMIA; HEALTH; HUMANS; INFLAMMATION; INTESTINES; LIPOPOLYSACCHARIDES; METAGENOME; OBESITY;

BACTERIA (MICROORGANISMS);

EID: 84859307224     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533611434934     Document Type: Review

References (131)

1. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002 ; 22: 283-307
2. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007 ; 104 (34). 13780-13785
3. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 ; 444 (7122). 1022-1023
4. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005 ; 308 (5728). 1635-1638
5. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 ; 444 (7122). 1027-1031
6. Relman DA. New technologies, human-microbe interactions, and the search for previously unrecognized pathogens. J Infect Dis. 2002 ; 186 (suppl 2). S254 - S258
7. Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol. 2010 ; 18 (7). 298-307
8. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999 ; 69 (5). 1035S - 1045S
9. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977 ; 31: 107-133
10. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008 ; 134 (2). 577-594
11. Ravin HA, Rowley D, Jenkins C, Fine J. On the absorption of bacterial endotoxin from the gastro-intestinal tract of the normal and shocked animal. J Exp Med. 1960 ; 112: 783-792
12. Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011 ; 31: 15-31
13. Laugerette F, Vors C, Geloen A, et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem. 2011 ; 22 (1). 53-59
14. Ghanim H, Sia CL, Upadhyay M, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr. 2010 ; 91 (4). 940-949
15. Deopurkar R, Ghanim H, Friedman J, et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care. 2010 ; 33 (5). 991-997
16. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care. 2009 ; 32 (12). 2281-2287
17. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007 ; 86 (5). 1286-1292
18. Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring). 2011 ; 19 (3). 476-482
19. Lassenius MI, Pietilainen KH, Kaartinen K, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011 ; 34 (8). 1809-1815
20. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011 ; 34 (2). 392-397
21. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care. 2010 ; 33 (9). 1925-1932
22. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010 ; 50 (6). 645-649
23. Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, Lehto M. Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with type 1 diabetes. Diabetes Care. 2009 ; 32 (9). 1689-1693
24. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V. Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscl Thromb Vasc Biol. 2007 ; 27 (6). 1433-1439
25. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 1998 ; 395 (6699). 284-288
26. Gamble L, Bagby GJ, Quinton LJ, et al. The systemic and pulmonary LPS binding protein response to intratracheal lipopolysaccharide. Shock. 2009 ; 31 (2). 212-217
27. Grube BJ, Cochane CG, Ye RD, et al. Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells. J Biol Chem. 1994 ; 269 (11). 8477-8482
28. Dixon DR, Darveau RP. Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid a structure. J Dent Res. 2005 ; 84 (7). 584-595
29. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008 ; 87 (5). 1219-1223
30. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res. 2009 ; 50 (1). 90-97
31. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008 ; 57 (6). 1470-1481
32. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009 ; 58 (8). 1091-1103
33. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007 ; 292 (2). G518 - G525
34. Kvietys PR, Specian RD, Grisham MB, Tso P. Jejunal mucosal injury and restitution: role of hydrolytic products of food digestion. Am J Physiol. 1991 ; 261 (3). G384 - G391
35. Velasquez OR, Place AR, Tso P, Crissinger KD. Developing intestine is injured during absorption of oleic acid but not its ethyl ester. J Clin Invest. 1994 ; 93 (2). 479-485
36. Velasquez OR, Henninger K, Fowler M, Tso P, Crissinger KD. Oleic acid-induced mucosal injury in developing piglet intestine. Am J Physiol. 1993 ; 264 (3). G576 - G582
37. Kvietys PR, Wilborn WH, Granger DN. Effect of atropine on bile-oleic acid-induced alterations in dog jejunal hemodynamics, oxygenation, and net transmucosal water movement. Gastroenterology. 1981 ; 80 (1). 31-38
38. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med. 2002 ; 195 (5). 559-570
39. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol. 1997 ; 158 (8). 3925-3934
40. Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van 't, Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003 ; 170 (3). 1399-1405
41. Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med. 1995 ; 182 (1). 267-272
42. Harris HW, Grunfeld C, Feingold KR, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest. 1993 ; 91 (3). 1028-1034
43. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994 ; 180 (3). 1025-1035
44. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins: their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979 ; 64 (5). 1516-1524
45. Navab M, Hough GP, Van Lenten BJ, Berliner JA, Fogelman AM. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest. 1988 ; 81 (2). 601-605
46. Drewe J, Beglinger C, Fricker G. Effect of ischemia on intestinal permeability of lipopolysaccharides. Eur J Clin Invest. 2001 ; 31 (2). 138-144
47. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011 ; 94 (1). 58-65
48. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010 ; 18 (1). 190-195
49. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009 ; 106 (7). 2365-2370
50. Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr. 2008 ; 88 (4). 894-899
51. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008 ; 32 (11). 1720-1724
52. Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010 ; 59 (12). 3049-3057
53. Santacruz A, Marcos A, Warnberg J, et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring). 2009 ; 17 (10). 1906-1915
54. Nadal I, Santacruz A, Marcos A, et al. Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond). 2009 ; 33 (7). 758-767
55. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010 ; 299 (2). G440 - G448
56. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009 ; 137 (5). 1716 e1711-1724 1712
57. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996 ; 4 (11). 430-435
58. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007 ; 50 (11). 2374-2383
59. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 ; 56 (7). 1761-1772
60. Takayama K, Qureshi N, Raetz CR, et al. Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun. 1984 ; 45 (2). 350-355
61. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006 ; 116 (11). 3015-3025
62. Kox M, de Kleijn S, Pompe JC, et al. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med. 2011 ; 39 (8). 1866-1870
63. Vaishnava S, Hooper LV. Alkaline phosphatase: keeping the peace at the gut epithelial surface. Cell Host Microbe. 2007 ; 2 (6). 365-367
64. Goldberg RF, Austen WG, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A. 2008 ; 105 (9). 3551-3556
65. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008 ; 15 (5). 506-516
66. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007 ; 316 (5831). 1628-1632
67. Mahmood A, Shao JS, Alpers DH. Rat enterocytes secrete SLPs containing alkaline phosphatase and cubilin in response to corn oil feeding. Am J Physiol Gastrointest Liver Physiol. 2003 ; 285 (2). G433 - G441
68. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther. 2003 ; 307 (2). 737-744
69. Malo MS, Alam SN, Mostafa G, et al. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut. 2010 ; 59 (11). 1476-1484
70. Campbell EL, MacManus CF, Kominsky DJ, et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A. 2010 ; 107 (32). 14298-14303
71. Buttenschoen K, Berger D, Strecker W, et al. Association of endotoxemia and production of antibodies against endotoxins after multiple injuries. J Trauma. 2000 ; 48 (5). 918-923
72. Schumann RR. Recognition of bacterial endotoxin and modulation of the inflammatory response: the LBP/CD14 pathway during the acute phase. Sepsis. 1998 ; 2: 149-155
73. Canny G, Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol. 2008 ; 29 (11). 541-547
74. Canny G, Cario E, Lennartsson A, et al. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am J Physiol Gastrointest Liver Physiol. 2006 ; 290 (3). G557 - G567
75. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002 ; 99 (6). 3902-3907
76. Levy O, Sisson RB, Kenyon J, Eichenwald E, Macone AB, Goldmann D. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo. Infect Immun. 2000 ; 68 (9). 5120-5125
77. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukocyte Biol. 1998 ; 64 (1). 14-18
78. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol. 1998 ; 10 (1). 45-49
79. Gazzano-Santoro H, Parent JB, Grinna L, et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun. 1992 ; 60 (11). 4754-4761
80. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest. 1990 ; 85 (3). 853-860
81. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol. 1999 ; 11 (1). 19-22
82. Levy O, Ooi CE, Elsbach P, Doerfler ME, Lehrer RI, Weiss J. Antibacterial proteins of granulocytes differ in interaction with endotoxin: comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol. 1995 ; 154 (10). 5403-5410
83. Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun. 1994 ; 62 (4). 1185-1191
84. Campbell EL, Serhan CN, Colgan SP. Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J Immunol. 2011 ; 187 (7). 3475-3481
85. Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob Agents Chemother. 1996 ; 40 (1). 65-69
86. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability- increasing protein in an animal model of gram-negative sepsis. J Infect Dis. 1995 ; 171 (1). 153-160
87. Manning PJ, Sutherland WH, McGrath MM, de Jong SA, Walker RJ, Williams MJ. Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring). 2008 ; 16 (9). 2046-2052
88. Jimenez-Gomez Y, Lopez-Miranda J, Blanco-Colio LM, et al. Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis. 2009 ; 204 (2). e70 - e76
89. Pacheco YM, Lopez S, Bermudez B, Abia R, Villar J, Muriana FJ. A meal rich in oleic acid beneficially modulates postprandial sICAM-1 and sVCAM-1 in normotensive and hypertensive hypertriglyceridemic subjects. J Nutr Biochem. 2008 ; 19 (3). 200-205
90. Bogani P, Galli C, Villa M, Visioli F. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis. 2007 ; 190 (1). 181-186
91. Cortes B, Nunez I, Cofan M, et al. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. J Am Coll Cardiol. 2006 ; 48 (8). 1666-1671
92. Edirisinghe I, Banaszewski K, Cappozzo J, et al. Strawberry anthocyanin and its association with postprandial inflammation and insulin. Br J Nutr. 2011 ; 106 (6). 913-922
93. Tang D, Kang R, Xiao W, et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol. 2009 ; 41 (6). 651-660
94. Chen HW, Kuo HT, Chai CY, Ou JL, Yang RC. Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia. J Endotoxin Res. 2007 ; 13 (1). 15-23
95. Hodin RA, Graham JR, Meng S, Upton MP. Temporal pattern of rat small intestinal gene expression with refeeding. Am J Physiol. 1994 ; 266 (1). G83 - G89
96. Nestel PJ, Pally S, Macintosh GL, et al. Circulating inflammatory and atherogenic biomarkers are not increased following single meals of dairy foods. Eur J Clin Nutr. 2012 ; 66 (1). 25-31
97. Esposito K, Nappo F, Giugliano F, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2003 ; 78 (6). 1135-1140
98. Blackburn P, Despres JP, Lamarche B, et al. Postprandial variations of plasma inflammatory markers in abdominally obese men. Obesity (Silver Spring). 2006 ; 14 (10). 1747-1754
99. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP. The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab. 1999 ; 84 (6). 2126-2133
100. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002 ; 39 (7). 1145-1150
101. van Wijk JP, Cabezas MC, Coll B, Joven J, Rabelink TJ, de Koning EJ. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis. 2006 ; 186 (1). 152-159
102. Khoury DE, Hwalla N, Frochot V, Lacorte JM, Chabert M, Kalopissis AD. Postprandial metabolic and hormonal responses of obese dyslipidemic subjects with metabolic syndrome to test meals, rich in carbohydrate, fat or protein. Atherosclerosis. 2010 ; 210 (1). 307-313
103. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr. 2004 ; 79 (4). 682-690
104. Papageorgiou N, Tousoulis D, Psaltopoulou T, et al. Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals. Eur J Clin Nutr. 2011 ; 65 (4). 514-519
105. Tholstrup T, Teng KT, Raff M. Dietary cocoa butter or refined olive oil does not alter postprandial hsCRP and IL-6 concentrations in healthy women. Lipids. 2011 ; 46 (4). 365-370
106. Poppitt SD, Keogh GF, Lithander FE, et al. Postprandial response of adiponectin, interleukin-6, tumor necrosis factor-alpha, and C-reactive protein to a high-fat dietary load. Nutrition. 2008 ; 24 (4). 322-329
107. Igarashi M, Hirata A, Yamauchi T, et al. Clinical utility and approach to estimate postprandial hypertriglycemia by a newly designed oral fat-loading test. J Atheroscl Thromb. 2003 ; 10 (5). 314-320
108. Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after a high-fat meal. Clin Sci (Lond). 2004 ; 106 (3). 315-319
109. Zahedi RG, Summers LK, Lumb P, Chik G, Crook MA. The response of serum sialic acid and other acute phase reactants to an oral fat load in healthy humans. Eur J Intern Med. 2001 ; 12 (6). 510-514
110. Lundman P, Boquist S, Samnegard A, et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Dis. 2007 ; 17 (3). 195-202
111. Dekker MJ, Wright AJ, Mazurak VC, et al. Fasting triacylglycerol status, but not polyunsaturated/saturated fatty acid ratio, influences the postprandial response to a series of oral fat tolerance tests. J Nutr Biochem. 2009 ; 20 (9). 694-704
112. Payette C, Blackburn P, Lamarche B, et al. Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism. 2009 ; 58 (11). 1593-1601
113. van der Meer W, Pickkers P, Scott CS, van der Hoeven JG, Gunnewiek JK. Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia. J Endotoxin Res. 2007 ; 13 (2). 94-100
114. Dorresteijn MJ, van Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P. Iso-osmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin Res. 2005 ; 11 (5). 287-293
115. Sauermann R, Marsik C, Steiner I, et al. Immunomodulatory effects of fosfomycin in experimental human endotoxemia. Antimicrob Agents Chemother. 2007 ; 51 (5). 1879-1881
116. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007 ; 35 (6). 1464-1469
117. Soop A, Albert J, Weitzberg E, Bengtsson A, Nilsson CG, Sollevi A. Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. Clin Exp Immunol. 2004 ; 135 (1). 114-118
118. Mayr FB, Spiel A, Leitner J, et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med. 2005 ; 171 (4). 354-360
119. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation. 2005 ; 111 (14). 1841-1846
120. Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol. 1995 ; 154 (3). 1499-1507
121. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996 ; 184 (5). 1601-1608
122. Pajkrt D, Camoglio L, Tiel-van Buul MC, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol. 1997 ; 158 (8). 3971-3977
123. Dekkers PE, Lauw FN, ten Hove T, et al. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood. 1999 ; 94 (7). 2252-2258
124. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000 ; 95 (4). 1124-1129
125. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000 ; 165 (5). 2783-2789
126. Bunnell E, Lynn M, Habet K, et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med. 2000 ; 28 (8). 2713-2720
127. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001 ; 58 (5). 445-452
128. Branger J, van den Blink B, Weijer S, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol. 2002 ; 168 (8). 4070-4077
129. Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis. 2003 ; 187 (4). 631-639
130. van Bockel EA, Tulleken JE, Muller Kobold AC, et al. Cardiac troponin I release and cytokine response during experimental human endotoxaemia. Intensive Care Med. 2003 ; 29 (9). 1598-1600
131. de Kruif MD, Lemaire LC, Giebelen IA, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007 ; 178 (3). 1845-1851